Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is an investigational multidrug cocktail developed by Atlantic Health System for the management of postoperative pain. The combination consists of four active ingredients: ropivacaine, a long-acting amide local anesthetic; epinephrine, a vasoconstrictor that prolongs the duration of the anesthetic; ketorolac, a nonsteroidal anti-inflammatory drug (NSAID) that provides systemic and local analgesia; and clonidine, an alpha-2 adrenergic agonist that enhances the effects of local anesthetics. The cocktail is administered via direct injection into the surgical site to provide multimodal analgesia, aiming to reduce postoperative narcotic consumption. It is currently being evaluated in Phase 2 clinical trials for patients undergoing soft tissue tumor resection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ropivacaine + epinephrine + ketorolac + clonidine (Atlantic Health System).